Emergent BioSolutions to Participate in Upcoming Investor Conferences

Emergent BioSolutions Inc. (NYSE: EBS), based in Gaithersburg, Maryland, has announced its participation in upcoming investor conferences, aiming to engage with the investment community and showcase its initiatives. The company will be represented by its senior management team at two significant events:

1. **Wells Fargo 20th Annual Healthcare Conference** - Scheduled for September 4, 2025, at 3:00 PM ET. Attendees can access the presentation via a provided webcast link and request one-on-one meetings through their conference representatives. 2. **HCW 27th Annual Global Investment Conference** - Taking place on September 9, 2025, at 1:30 PM ET, this event will similarly feature a webcast for presentations and opportunities for personalized discussions.

Emergent BioSolutions focuses on public health defense through the development of life-saving products that address a variety of health threats, including smallpox, mpox, botulism, Ebola, anthrax, and challenges related to opioid overdoses. With over 25 years of experience in this critical sector, the company’s mission remains centered on protecting and saving lives, thereby fortifying public health measures globally.

Investors interested in following the company's presentations can do so through the Investors page on Emergent’s website, where recorded sessions will also be available. The company emphasizes its commitment to keeping the community informed about its strategies and plans to tackle contemporary health challenges and future preparedness.

For media inquiries, Assal Hellmer, Vice President of Communications, is available, while investor-related questions can be directed to Richard S. Lindahl, Executive Vice President and CFO. As Emergent continues to navigate its crucial role in public health, these conferences represent opportunities for transparency and dialogue with stakeholders.

Emergent BioSolutions Inc. (NYSE: EBS) has announced its participation in upcoming investor conferences, which may provide a vital platform for communication and visibility in the market. The company’s commitment to public health, particularly in areas like bioterrorism and infectious disease prevention, positions it uniquely within its sector.

As investors consider their positions, it is essential to assess the implications of these conferences. The Wells Fargo 20th Annual Healthcare Conference on September 4 and HCW 27th Annual Global Investment Conference on September 9 will enable Emergent's senior management to engage directly with investors. This may result in valuable insights into current developments, strategic initiatives, and projections moving forward.

Given Emergent's focus on high-stakes health threats, the conferences are also an opportunity for the company to emphasize innovative products and partnerships that could drive future growth. With increasing global attention on biopharmaceuticals, especially post-pandemic, the company's portfolio may attract renewed interest. Investors should pay attention to key messages from these presentations regarding pipeline advancements and regulatory approvals.

The webinars and potential one-on-one meetings present a strategic chance to glean more personalized insights into the business. Investors should consider reaching out for these meetings to cultivate a more nuanced understanding of the company’s trajectory and management's vision.

In light of recent market volatility in the healthcare sector, potential investors may find this an opportune time to evaluate Emergent BioSolutions. While high-risk, high-reward investments are often in demand, Emergent’s established history and public health mission could provide a robust foundation for long-term growth. Monitoring these conference outcomes will be critical in making informed investment decisions.